secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2025-08-22T23:59:59+00:00
Accession:  0001104659-25-081953
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance Biotherapeutics enters $350M ATM equity offering agreement with Jefferies
--------------------------------------------------------------------------------

- Agreement with Jefferies LLC to sell up to $350M of common stock in at-the-market offerings.
- Jefferies will receive 3.0% commission on gross proceeds from any shares sold.
- Sales may be made from time to time at the Company's discretion; no obligation to sell.
- Prospectus supplement dated August 22, 2025, filed under existing S-3ASR registration statement.
- Agreement is an amendment and restatement of prior open market sale agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925081953/0001104659-25-081953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925081953/tm2524060d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-081953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer